Heme Gene Panel by NGS

single page view

General Information

Lab Name
Heme Gene Panel by NGS
Lab Code
HCAPA
Epic Ordering
Heme Gene Panel by NGS
Description

This assay is a multiplexed gene sequencing panel designed to detect mutations associated with hematologic myeloid and lymphoid disorders. Purified genomic DNA is enzymatically sheared and targeted sequences are isolated by hybrid capture probes and sequenced by using an Illumina NGS platform.

This assay will not detect variants if present in only a small proportion of cells in the sample. If indicated, additional testing for FLT3-ITD and CEBPA mutations for new evaluation of acute myeloid leukemia should be separately ordered.

This assay is not intended for post-treatment disease monitoring nor comprehensive germline evaluation and is not validated to detect all classes of genomic alterations, such as large structural events including fusions and copy alterations.

If indicated, separate panel-based testing can be performed for myeloid-focused genes (HCAPMY) or lymphoid-focused genes (HCAPL). This assay is focused on hematologic disorders; for solid tumor testing, consider UW-Oncoplex testing.

SNV
Limit of Detection: 3%
Limit of Quantification: 4%
Precision near LOD (CV): 20%
Accuracy: 100% of expected variants

INDELS
Limit of Detection: 3%
Limit of Quantification: Qualitative Only
Precision near LOD (CV): 20%
Accuracy: 98% of expected insertions/deletions

Hematopathology test request form can be found at Request Form

Synonyms
ABL1 (exons 01-11), Acute myeloid leukemia, ALK (exons 01-29), ANKRD26 (exons 01-34), ASXL1 (exons 01-12), ATM (exons 02-63), B cell lymphoma, B lymphoblastic leukemia, BCL2 (exons 02-03), BCOR (exons 02-15), BCORL1 (exons 01-12), BIRC3 (exons 03-10), BRAF (exons 01-18), BTK (exons 02-19), CARD11 (exons 02-25), CBL (exons 01-16), CBLB (exons 01-19), CCND1 (exons 01-05), CD19 (exons 01-15), CD274 (exons 02-07), CD74 (exons 01-09), CD79B (exons 01-06), CDKN2A (exons 01-03), chronic lymphocytic leukemia, CSF3R (exons 03-17), CXCR4 (exons 01-02), DDX41 (exons 01-17), DNMT3A (exons 02-23), EP300 (exons 01-31), essential thrombocythemia, ETNK1 (exons 01-08), ETV6 (exons 01-08), EZH2 (exons 02-20), FBXW7 (exons 02-12), FGFR1 exons (02-18), FLT3 (exons 01-24), GATA1 (exons 01-06), GATA2 (exons 02-06), HRAS (exons 02-06), IDH1 (exons 03-10), IDH2 (exons 01-11), JAK2 (exons 03-25), KIT (exons 01-21), KMT2A (exons 01-36), KMT2D (exons 01-54), KRAS (exons 02-05), lymphoplasmacytic lymphoma, MAP2K1 (exons 01-11), marginal zone lymphoma, marrow failure, mastocytosis, MDS, MPL exons (01-12), MPN, MYC (exons 01-03), MYD88 (exons 01-05), myelodysplasia, myeloid stem cell neoplasm, myeloproliferative neoplasms, NF1 (exons 01-57), NOTCH1 (exons 01-34), NOTCH2 (exons 01-22), NPM1 (exons 01-11), NRAS (exons 02-05), PDGFRA (exons 02-23), PDGFRB (exons 02-23), PHF6 (exons 02-10), PLCG2 (exons 02-33), polycythemia vera, PPM1D (exons 01-06), primary myelofibrosis, PTEN (exons 01-09), PTPN11 (exons 01-15), RAD21 (exons 02-14), RB1 (exons 01-27), RHOA (exons 02-05), RUNX1 (exons 01-09), SAMD9 (exons 01-03), SAMD9L (exon 05), SETBP1 (exons 02-06), SF3B1 (exons 01-25), SH2B3 (exons 02-08), SMC1A (exons 01-25), SMC3 (exons 01-29), SRSF2 (exons 01-02), STAG2 (exons 02-33), STAT3 (exons 02-24), STAT5B (exons 02-19), STAT6 (exons 02-22), T lymphoblastic leukemia, TCF3 (exons 02-19), TET2 (exons 02-11), TNFAIP3 (exons 02-09), TNFRSF14 (exons 01-08), TP53 (exons 02-11), U2AF1 (exons 01-08), WT1 (exons 01-10), XPO1 (exons 02-25), ZRSR2 (exons 01-11)
Components

Interpretation

Method

Next-Generation Sequencing

Reference Range
See individual components

Ordering & Collection

Specimen Type
Blood, Bone Marrow, Tissue - Fresh, frozen or FFPE/PET (Blocks), Fluids, Slides, Sorted Cells
Collection

Preferred:
Blood: 6mL in Lavender Top (EDTA)

Bone Marrow: 1-2mL in Lavender Top (EDTA)

Tissue, Fluids or Sorted cells: Sterile container in RPMI

Formalin-fixed paraffin embedded tissue (FFPE/PET) block

Slides: 10 unstained

Accepted:
Green Tops (Heparin), while green tops are accepted for testing, there is documentation that heparin can interfere with some PCR assays.

Extracted DNA from CLIA certified laboratory.

Formalin-fixed paraffin embedded tissue (FFPE/PET)

Tissue from curls cut from FFPE/PET blocks or stained cover-slipped slides


Unacceptable:
Specimens received beyond stability limit.
Specimens with low volume or inadequate WBC
Decalcified or unacceptable fixatives

Handling Instructions
  • Deliver samples to Hematopathology as soon as possible.
  • If sample is older than 48 hours, please store at 2-6°C upon receipt and send refrigerated.
  • Samples stored at room temperature or refrigerated older than 7 days will be rejected.
  • Frozen samples should be shipped on dry ice.
Quantity
requested: Blood: 6mL EDTA/BMA: 1-2mL EDTA/Tissue Blocks: Adequate size to cut 10-20 curls/Slides: 10 unstained
minimum: Blood: 1mL EDTA/ BMA: 0.5mL EDTA/Tissue Blocks: 5 curls/Slides: 5 slides

Processing

Processing

Send specimens to Hematopathology – Molecular department for processing.
The stability limit for Blood and Bone Marrow is 7 days, samples beyond this limit will be rejected.

Blood and BMA must arrive in lab by 7am and tissue by 12pm Friday to be included on Monday run.

Performance

LIS Dept Code
Molecular Hematopathology (MHP)
Performing Location(s)
Other Hematopathology, Molecular
206-606-7060

UW Hematopathology Laboratory, G7-800
Fred Hutchinson Cancer Center
825 Eastlake Avenue E.
Seattle, WA 98109

Hematopathology, Molecular hours:
7:00 am - 5:30 pm M-F
8:00 am - 4:30 pm Saturday, closed on Sunday, and with reduced staffing on major holidays
Frequency
Monday: Results within 12 - 14 days from start of testing. Cases requiring repeat testing, review, or addressing other considerations may have a delay of ~ 12 additional days.
Available STAT?
No

Billing & Coding

CPT codes
81455
LOINC
51967-8
Interfaced Order Code
UOW3810